Pulmonary fibrosis treatment

Pulmonary fibrosis is a progressive interstitial lung disease characterized by irreversible scarring of lung tissue, leading to impaired gas exchange and worsening shortness of breath. The most common form, idiopathic pulmonary fibrosis, has historically carried a poor prognosis, but therapeutic advances have begun to alter its trajectory. Pulmonary fibrosis treatment currently focuses on slowing disease progression, alleviating symptoms, and preserving quality of life. Antifibrotic medications such as pirfenidone and nintedanib have demonstrated effectiveness in reducing lung function decline, and ongoing research is investigating additional agents targeting novel pathways of inflammation and fibrosis. Supportive therapies remain essential: pulmonary rehabilitation enhances exercise tolerance, oxygen supplementation relieves hypoxemia, and vaccination reduces infection risks. In carefully selected patients, lung transplantation offers the only curative option, though it requires extensive evaluation and lifelong immunosuppression. Equally important is early and accurate diagnosis, as distinguishing pulmonary fibrosis from other interstitial lung diseases ensures appropriate treatment initiation. Patient-centered care also addresses psychological support, palliative options, and education on lifestyle adjustments. Advances in biomarker discovery and genetic research hold promise for more precise, individualized therapies in the near future. The evolving landscape of pulmonary fibrosis treatment reflects a shift from purely supportive care toward targeted, proactive, and personalized disease management strategies.